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ABSTRACT  
Background and Aims: Genetic variation in both patatin-like phospholipase domain-containing 
protein-3 (PNPLA3) (I148M) and the transmembrane 6 superfamily member 2 protein (TM6SF2) 
(E167K) influences severity of liver disease, and serum triglyceride concentrations in non-alcoholic 
fatty liver disease (NAFLD), but whether either genotype influences the responses to treatments is 
uncertain.  
Methods: 103 patients with NAFLD were randomised to omega-3 fatty acids (DHA+EPA) or placebo 
for 15-18 months in a double blind placebo-controlled trial. Erythrocyte enrichment with DHA and 
EPA was measured by gas-chromatography. PNPLA3 and TM6SF2 genotypes were measured by PCR 
technologies. Multivariable linear regression and analysis of covariance were undertaken to test the 
effect of genotypes on omega-3 fatty acid enrichment, end of study liver fat percentage and serum 
triglyceride concentrations. All models were adjusted for baseline measurements of each respective 
outcome. 
Results: 55 men and 40 women (Genotypes PNPLA3 I148M, CC=41, CG=43, GG=11; TM6SF2 E167K 
CC=78, CT+TT=17 participants) (mean ±SD age, 51±11 years) completed the trial. Adjusting for 
baseline measurement, measured covariates and confounders, PNPLA3 (I148M) GG genotype was 
independently associated with % DHA enrichment (B coefficient -1.02 (95%CI -1.97, -0.07), p=0.036) 
but not % EPA enrichment (B coefficient -0.31 (95%CI -1.38, 0.75), p=0.56). This genotype was also 
independently associated with end of study % liver fat (B coefficient 9.5 (95%CI 2.53, 16.39), 
p=0.008), but not end of study triglyceride concentration (B coefficient -0.11 (95%CI -0.64, 0.42), 
p=0.68). 
Conclusions: PNPLA3 (I148M) GG genotype influences the changes in liver fat and DHA tissue 
enrichment during the trial but not the change in serum triglyceride concentration. 
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INTRODUCTION 
Non-alcoholic fatty liver disease (NAFLD) is strongly associated with type 2 diabetes, 
metabolic syndrome (MetS) (1) and weight loss (2). Omega-3 polyunsaturated fatty acid 
(PUFA) treatment (3) and weight loss (4) can be effective in decreasing liver fat and also 
triglyceride concentrations. Recently in patients with NAFLD we have suggested that the 
omega-3 fatty acid docosahexaenoic acid (DHA, 22:6n-3) may be more effective that the 
omega-3 fatty acid eicosapentanoic acid (EPA; 20:5n-3) in decreasing liver fat (5). In this 
randomised placebo-controlled trial that tested the effects of high dose purified omega-3 
fatty acids, we showed an association between high levels of erythrocyte DHA, but not EPA, 
enrichment and decreased liver fat. Similarly, and in support of our findings, others have 
shown a benefit of omega-3 fatty acids to decrease liver fat, both in adults (6) and in 
children (7) with NAFLD. Although these findings are all consistent with the results of a 
recent systematic review and meta-analysis showing a benefit of omega-3 fatty acid 
treatment on liver fat in NAFLD (8), a recent trial that used high doses of EPA only, failed to 
show an improvement in NAFLD histological score (9).  The reason for this apparent 
discrepancy in findings between the effects of DHA and EPA in NAFLD is uncertain, but there 
is considerable evidence that EPA and DHA have different biological effects in man (10-13) 
(14).  
In NAFLD, patients with the homozygous GG (I148M) gene variant of the patatin-like 
phospholipase domain-containing protein-3 (PNPLA3) have higher levels of liver fat 
accumulation (15, 16) and lower serum fasting TG concentration, compared to those 
without the homozygous gene variant (17). The precise mechanism by which variation in 
PNPLA3 genotype induces hepatic lipid accumulation and decreased fasting triglyceride 
concentration is not clear. With regard to regulation of liver lipid, PNPLA3 exhibits both 
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acyltransferase activity and TG hydrolase activity (18). The PNPLA3 I148M GG genotype has 
been shown to reduce secretion of large TG-rich VLDL particles in obese men with hepatic 
steatosis and to impair apoB100 secretion (19). Moreover, the PNPLA3 I148M GG genotype 
is known to facilitate the differential incorporation into liver lipid droplets of different types 
of fatty acid, for example vaccenic and palmitoleic acids, thereby altering the fatty acid 
composition of the lipid droplets (20). Recent data suggest that in humans PNPLA3 I148M 
regulates the efflux and remodelling, but not the influx, of lipid into hepatic lipid droplets 
(17, 20-22). In mice, Peter et al. (23) have shown that PNPLA3I148M GG genotype is 
characterised by a decrease in lipolytic activity and lysophosphatidic acid acyl-CoA 
transferase activity, with a greater than twofold preference for PUFAs. These investigators 
also showed that there was a reduction of DHA in the hepatocytes of mice overexpressing 
PNPLA3 I148M GG genotype. Additionally, Ruhanen et al (20) have shown that fatty acid 
composition was altered in cells expressing PNPLA3 I148M GG genotype with an increase of 
18:1 n-7 and 16:1 n-7 (vaccenic and palmitoleic acids, respectively).  
Moreover, recent studies have also identified that genetic variation in the transmembrane 6 
superfamily member 2 protein (TM6SF2) at rs58542926 influences NAFLD severity, and 
contributes to lower levels of fasting triglycerides (24, 25). Although genetic variation in 
both PNPLA3 and TM6SF2 is known to influence severity of liver disease, and fasting serum 
triglyceride concentrations in NAFLD, it is presently uncertain whether either genotype 
influences the responses to treatments for NAFLD. The aim of our study was to test whether 
either PNPLA3 (I148M) or TM6SF2 (E167K) genotypes affected: a) the level of DHA and EPA 
enrichment; b) end of study liver fat percentage and c) end of study fasting triglyceride 
concentration, in patients with NAFLD treated for 15-18 months with DHA+EPA. The present 
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study was a sub-study of the randomised placebo-controlled WELCOME trial (5, 26) (Wessex 
Evaluation of fatty Liver and Cardiovascular markers in NAFLD with OMacor thErapy;  
www.clinicalTrials.gov registration number NCT00760513) in which liver fat percentage and 
fasting serum triglyceride concentrations decreased due to DHA+EPA treatment and weight 
loss observed during the trial. 
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PATIENTS AND METHODS 
Study design  
The WELCOME trial was a double blind placebo-controlled trial where we tested the effect 
of 4 g per day of Omacor (1 g of Omacor contains 460 mg of EPA and 380 mg of DHA as ethyl 
esters) or placebo for 15-18 months on liver-related primary outcomes in patients with 
NAFLD (26). Omacor, also known as Lovaza, was provided free of charge by Pronova 
BioPharma/Abbott (Pronova BioPharma ASA, Lysaker, Norway; Abbott Laboratories, 
Southampton, UK).  
Subjects and measurements 
We randomised 103 participants to either DHA+EPA (n=51) or placebo (n=52) and 95 
participants completed the study (DHA+EPA=47; placebo=48). Consort diagram and the 
baseline characteristics of both placebo and active groups have been reported previously 
(5). All participants had NAFLD and features of metabolic syndrome. Metabolic syndrome 
was defined using the International Diabetes Federation criteria (27), the criteria for 
defining NAFLD were reported previously (26). Blood pressure was measured using a 
Marquette Dash 3000 monitor (GE Healthcare, Little Chalfont, Bucks, UK) in the non-
dominant arm. Waist circumference was measured over bare skin, midway between the 
costal margin and the iliac crest. Hip circumference was measured at the widest part 
between the greater trochanter and lower buttock level. Radiological assessments of body 
fat (dual-energy X-ray absorptiometry, DEXA) were undertaken at both baseline and end of 
study. DEXA scanning was undertaken with a Delphi W instrument (Hologic, Bedford, MA, 
USA) to assess percentage body fat, fat distribution and lean mass. Glucose, insulin, total 
cholesterol, HDL-cholesterol, TG, alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) and cytokeratin-18 (CK-18 M65 as a marker of liver apoptosis (28)) 
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were measured in fasting serum. For measurement of serum TG concentration, the intra-
assay coefficient of variation (CV) was 1% and the inter-assay CV was 1.7%, for TG 
concentrations < 88.5 mg/dL. Magnetic resonance imaging (MRI) of abdominal visceral and 
subcutaneous fat and MR spectroscopy of hepatic lipid content were undertaken at the 
beginning and at the end of the study. Any change in diet during the study was assessed by 
food frequency questionnaire and we also generated a ‘prudent diet score’ as a healthy diet 
index, using principal component analyses (29). Drug medication was recorded at each 
study visit. At 6 months, 12 months and end of study, participants returned all used study 
capsules. Returned capsules were counted to assess compliance to allocated DHA+EPA or 
placebo.  
DHA and EPA enrichment in erythrocytes 
We measured DHA and EPA in erythrocytes at the beginning and at the end of the 
treatment by gas chromatography (30, 31). Enrichment was defined as the difference 
between end of study and baseline measurements.  Total lipids were extracted from thawed 
packed erythrocytes (300 µl) with 5 ml chloroform:methanol (2:1 v/v) containing butylated 
hydroxytoluene (50 mg/L) (32). Fatty acid methyl esters (FAMEs) were synthesised by 
heating the total lipid extract with 1 ml methanol containing 2% (vol/vol) H2SO4 at 50°C for 2 
h (30), FAMEs were extracted with hexane and analysed using a Hewlett Packard 6890 gas 
chromatograph fitted with a BPX-70 fused silica capillary column (30 m x 0.22 mm x 0.25 
μm) with flame ionisation detection (30).  FAMEs were identified by comparison of 
retention times with those of authentic standards. Intra-assay CVs for EPA and DHA were 
3.0% and 2.0% respectively. Inter-assay CVs for EPA and DHA were 5.0% and 2.2% 
respectively.  
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DNA analyses  
Blood was collected from participants at baseline for determination of polymorphisms in the 
gene encoding PNPLA3. DNA was extracted from 200 μl whole blood using QIAamp blood 
DNA blood mini kit (Qiagen, 51106), as per manufacturer’s instructions.  All samples were 
eluted in 200 μl DNAse free water. Quality and quantity of DNA was confirmed by 
spectrophotometry using a Nanodrop 2000 (Thermo Scientific), where all samples had a 
260/280 ratio ≥1.8. PCR primers (Table. 1) were designed using PyroMark Assay Design 2.0 
software (Biotage) to investigate the SNP rs738409 in the human PNPLA3-I148M gene 
variant. PCR was carried out on 25 ng DNA using 25 μl KAPA2G Robust Hot Start Taq 
(Anachem, KK5702) and 0.2μM of forward (5’ AGCAGAGAAAGCCGACTTACCAC 3’) and 
reverse (5’ GGGTGCTCTCGCCTATAACTTC 3’) primers in a 50 μl reaction. PCR products were 
immobilised on streptavidin–sepharose beads (GE Healthcare UK Ltd., 17-5113-01), washed, 
denatured and released into annealing buffer containing the sequencing primer (5’ 
ATGTTCCTGCTTCAT 3’).  PNPLA3 SNP genotype was analysed using Pyromark ND 1.0 
Software (Biotage). TM6SF2 genotype was determined using TaqMan C_89463510_10 
Genotyping assay (Life technologies 4351379) and TaqMan Genotyping Master Mix (Life 
Technologies, 4371353) and analysed using LightCycler 480 SW 1.5.1 software (Roche). The 
rs58542926 C>T (E167K, TM6SF2) single-nucleotide polymorphisms were assessed in 
duplicate. Analytical pass rate was 100%.  
Statistical analyses 
All statistical analyses were performed using SPSS for Windows (version 21.0; SPSS). We 
examined baseline and end of study characteristics in DHA+EPA and placebo groups. Data 
are reported as means and 95% CIs or SDs for normally distributed variables, or as median 
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and interquartile range (IQR), or ranges with maxima and minima for non-normally 
distributed variables. Comparisons of means between groups were performed by using t-
tests for normally distributed variables and Mann Whitney U for non-normally distributed 
unpaired variables. Comparisons of paired data were tested by paired t tests, Wilcoxon 
signed rank and McNemar’s tests. Multivariable linear regression modelling with backwards 
elimination was undertaken to test independent associations with these outcome variables: 
a) end of study TG concentration, b) end of study liver fat % c) DHA or EPA percentage 
enrichment in erythrocytes (end of study % minus baseline %). In each of these separate 
regression models, we adjusted for the baseline measurement of the outcome measure in 
question. Covariates, potential confounders and change in potential confounders between 
baseline and end of study were included, to test the independence of associations between 
key exposures and the outcome in question. Explanatory variables that were included in the 
models were continuous or categorical. For PNPLA3 and TM6SF2 genotype, a binary 
indicator variable was created and coded as CG+CC=0 and GG=1, or CC=0 and CT+TT=1 
respectively. Differences between variables in PNPLA3 genotype groups and in TG quartile 
groups were tested by ANOVA or Kruskal Wallis depending on whether variables were 
normally or non-normally distributed. A P value of < 0.05 was considered to be statistically 
significant. ANCOVA analyses were also undertaken test the effects of allelic variation of the 
genotypes for PNPLA3 and TM6SF2 on the study outcomes and to estimate the adjusted 
mean differences, according to genotype, between baseline and end of study in the study 
outcomes. Each ANCOVA model was adjusted for the same potential confounders as shown 
in the linear regression models. 
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RESULTS 
Subject characteristics 
Table 1 shows the baseline and end-of-study results for the main anthropometric and 
biochemical variables, according to randomization group. Ninety-five participants 
completed the study (55 men and 40 women) and 32 of these had diabetes. At baseline, 
fasting TG concentration and BMI were higher in the DHA+EPA group compared with the 
placebo group (p=0.04 and p=0.02, respectively). At baseline, there were no differences 
between the groups in MRI visceral fat measurements, waist circumference and weight. At 
baseline, 7.4% (n=7) of participants were taking fibrates, 6.3% (n=6) were taking ezetimibe, 
44.2% (n=42) were taking statins, 4.2% (n=4) were taking orlistat and 9.5% (n=9) were taking 
Levothyroxine. At the end of the study, there were 9.5% (n=9) of people taking fibrates, 
5.3% (n=6) people were taking ezetimibe, 49.5% (n=47) people taking statins, 1.1% (n=1) 
were taking orlistat (Table 1), 10.5% (n=10) were taking Levothyroxine. With regard to other 
metabolic and biochemical variables, there were no significant differences between 
randomisation groups (Table 1). Diet (assessed by prudent diet score) and alcohol intake did 
not change significantly during the study in either group. Capsule count at 6 months, 12 
months and at end of study confirmed that compliance with treatment was at least 78% of 
all allocated capsules in all participants during the duration of the study. No serious adverse 
events occurred that were attributed to DHA+EPA or placebo.  
Table 1 also shows fatty acid percentages in erythrocytes at baseline and at the end of study 
in the placebo and DHA+EPA groups. Despite very good compliance with the DHA+EPA 
intervention in the treatment arm, there was very variable DHA and EPA enrichment 
between individuals. Some individuals had only limited enrichment of either fatty acid while 
others had excellent enrichment, which did not relate to numbers of capsules consumed. 
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For example, for DHA and EPA, the range of change in concentrations in erythrocyte 
membranes was from -1.8% to +5.6% (DHA) and from -0.9% to +6.2% (EPA). In the placebo 
group, there was no change in enrichment in EPA and there was a very small increase in 
DHA enrichment. 
In our cohort, at baseline 42 participants had the PNPLA3 (I148M) CC genotype, 43 had the 
CG genotype and 13 had the GG genotype. Table 2 describes the baseline characteristics of 
the cohort stratified by PNPLA3 genotype. There were between group differences for DHA % 
(p=0.03).  With regard to TM6SF2 (E167K) genotype, 80 participants had the CC genotype, 
15 had the CT genotype and 3 had the TT genotype (Table 3).  
 
The effects of PNPLA3 (I148M) and TM6SF2 (E167K) genotypes on DHA and EPA 
enrichment  
We then tested whether PNPLA3 (I148M) GG genotype was independently associated with 
either erythrocyte DHA or EPA % enrichment between baseline and end of study. For DHA 
enrichment, the multivariable linear regression model included % change in erythrocyte 
DHA enrichment (end of study – baseline % enrichment) as the outcome, and age, sex, 
baseline liver fat %, PNPLA3 (I148M) GG genotype, TM6SF2 genotype CT+TT, BMI, diabetes, 
% DHA enrichment at baseline, total fat mass, change in CK-18 M65 (between end of study 
and baseline), triglyceride concentration at baseline, use of orlistat, L thyroxine, fibrates, 
beta blockers, and thiazide diuretics at baseline and capsule count. In this model, PNPLA3 
(I148M) GG was independently associated with % DHA enrichment (unstandardized B 
coefficient enrichment -1.02 (95%CI -1.97, -0.07), p=0.036). In contrast, when this regression 
model was adjusted to test associations between PNPLA3 (I148M) GG genotype and % EPA 
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enrichment, there was no significant association (unstandardized B coefficient -0.31 (95%CI 
-1.38, 0.75), p=0.56). TM6SF2 genotype was not independently associated with either EPA 
or DHA enrichment.  
 
Effect of PNPLA3 and TM6SF2 genotypes on end of study liver fat percentage and end of 
study triglyceride concentration 
Between baseline and end of study the change in liver fat % was -7.0 (14) (median and IQR) 
in the PNPLA3 (CC+CG) genotype groups compared with +1.2 (9.0) (median and IQR) in the 
GG group (p=0.027). The change in liver fat was -4% (20) (median and IQR) in the TMS6SF2 
CC genotype and in the TMS6SF2 CT+TT genotype it was 0.75 (12.3) (median and IQR). 
Between baseline and end of study the change in serum triglyceride concentration was 
(median and IQR) -0.1 (0.8) in the PNPLA3 (CC+CG) genotype groups compared with +0.3 
(0.9) in the GG group (p=0.22). In presence of the TMS6SF2 CC genotype the changes in 
triglycerides were -0.1 mmol/L (0.8) (median and IQR) and -0.1 mmol/L (0.6) (median and 
IQR) in the TMS6SF2 CT+TT genotype group respectively. 
The effect of PNPLA3 (I148M) GG genotype on end of study liver fat percentage and end of 
study triglyceride concentration was then investigated adjusting for covariates and potential 
confounders. From the results of univariate analyses (data not shown), for liver fat %, 
factors included in the regression modelling included age, sex, baseline liver fat %, PNPLA3 
genotype, TM6SF2 genotype CT+TT, BMI, diabetes, % DHA enrichment (end of study % – 
baseline % DHA), baseline serum triglyceride, total fat mass, change in M65 (between end of 
study and baseline), use of orlistat at baseline, use of L thyroxine at baseline and capsule 
count. Table 4 shows the only factors that were independently associated with end of study 
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liver fat %. DHA enrichment and decrease in weight (kg) during the 15-18 months of the 
trial, were both independently associated with end of study % liver fat and baseline % liver 
fat was also independently associated with end of study % liver fat. Additionally, PNPLA3 
(I148M) GG genotype was independently associated with end of study % liver fat (B 
coefficient B coefficient 9.5 (95%CI 2.53, 16.39), p=0.008). Overall this model (Table 4) 
accounted for 54% of the variance in end of study % liver fat (R2=0.54, p<0.0001).  
The effect of PNPLA3 (I148M) GG genotype on end of study triglyceride concentration was 
then investigated. From the results of univariate analyses (data not shown), factors included 
in the model, were age, sex, baseline liver fat %, MRS difference, PNPLA3 genotype, TM6SF2 
genotype CT+TT, BMI, diabetes, % EPA enrichment (end of study – baseline % enrichment), 
total fat mass, change in M65 (between end of study and baseline), triglyceride 
concentration at baseline, and use of orlistat, L thyroxine, fibrates, beta blockers, and 
thiazide diuretics at baseline, and capsule count. Factors that were independently 
associated with end of study triglyceride concentrations are shown in Table 5. In contrast to 
the data for end of study % liver fat, PNPLA3 genotype GG (I148M) was not associated with 
end of study triglyceride concentration (B coefficient -0.11 (95%CI -0.64, 0.42), p=0.68). 
Additionally, % EPA enrichment (B coefficient -0.19 (95%CI -0.31, -0.07), p=0.002) and not % 
DHA enrichment was independently associated with end of study triglyceride concentration. 
Factors included in the regression model shown in Table 5 explained 56% of the variance in 
end of study triglyceride concentration (R2=0.56, p<0.0001). We did not find any 
relationship between TMS6SF2 genotype and MRS liver fat or fasting triglyceride 
concentrations. However, we observed a significant difference in fasting TG at baseline by 
genotype; for the TMS6SF2 CT+TT genotype, triglycerides at baseline were lower (1.5 
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mmol/L (0.7) (median and IQR)) than for the TMS6SF2 CC genotype (1.8 mmol/L (1.4) 
(median and IQR)) (p=0.02).  
Since the evidence suggests that PNPLA3 (I148M) G/G genotype influences hepatic fat 
accumulation and liver damage with an additive effect of each G allele (33, 34), we tested 
the additive effective of allelic variation for PNPLA3 (I148M) genotype on change in liver fat 
percentage and change in fasting serum triglyceride between baseline and end of study.  
Each ANCOVA model (Table 6) was adjusted for the same potential confounders as shown in 
Tables 4 and 5. These data show that although there was a change in liver fat % between 
baseline and end of study in each PNPLA3 genotype the adjusted mean difference in liver fat 
% was greater for PNPLA3 I148I C/C and for PNPLA3 I148IM C/G (with a decrease in liver fat 
% between baseline and end of study), compared with the PNPLA3 I148M G/G group where 
there was a small increase in liver fat %. For change in triglyceride concentration between 
baseline and end of study, there was no significant effect of PNPLA3 genotype (in keeping 
with the results of regression modelling presented in Table 5). 
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DISCUSSION 
The novel results of our study are that in patients with NAFLD, the PNPLA3 (I148M) GG 
genotype, and not either the TM6SF2 (E167K) CT+TT or CC genotypes, was associated with 
markedly higher end of study liver fat percentage and lower DHA tissue enrichment (after 4 
g DHA+EPA intervention for 15-18 months). In contrast, neither PNPLA3 (I148M), nor 
TM6SF2 (E167K) genotypes were associated with end of study serum triglyceride 
concentrations. As can be seen in Table 4, after adjusting for baseline % liver fat, baseline 
body fat mass, and other covariates and confounders, the key independent factors 
associated with end of study liver fat %, were a decrease in weight during the trial, baseline 
body fat, an increase in tissue % DHA enrichment, PNPLA3 (I148M) GG genotype, and 
baseline liver fat %. Differences between baseline and end of study of participant 
characteristics, according to PNPLA3 (I148M) genotype are shown in the Supplementary 
Table.  
Previously, the strength of effect of the PNPLA3 (I148M) GG genotype on liver fat has been 
assessed in a meta-analysis of 16 studies (2,937 subjects) across different populations with 
NAFLD. In this analysis, PNPLA3 (I148M) GG genotype was associated with 73% higher liver 
fat content compared with the CC variant (33). In keeping with this evidence, in our subjects 
at baseline, median liver fat percentage was 28.5% in subjects with PNPLA3 (I148M) GG 
compared with 22.6% in subjects with CC or CG. However, to date it is uncertain how 
PNPLA3 (I148M) GG genotype modifies any response to treatment interventions in NAFLD. 
Very recently it has been suggested that there was a greater reduction in % liver fat with a 
12 month lifestyle intervention in subjects with the PNPLA3 (I148M) GG genotype (35) than 
in subjects with CG or CC genotype. However, initial baseline mean % liver fat in the 
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intervention group was surprisingly low (i.e. 5.5%) and was only 4.3% in the PNPLA3 (I148M) 
GG group.  As can be seen from our results and from the unstandardized B coefficient in 
Table 4, even after adjusting for baseline liver fat %, PNPLA3 (I148M) GG genotype was 
associated with 10% higher end of study liver fat than seen in subjects with either PNPLA3 
CC or CG. Importantly, this effect of PNPLA3 (I148M) GG genotype was independent of any 
benefit conferred by decrease in body weight and increased %DHA enrichment (Table 4).  
DHA+EPA treatment produced highly variable inter-individual DHA and EPA tissue 
enrichment, and importantly this enrichment was independent of compliance and the 
numbers of capsules returned unused during the trial. PNPLA3 (I148M) GG was associated 
with decreased DHA enrichment but was not associated with EPA enrichment. It is known 
that omega-3 fatty acids are rapidly incorporated into plasma membranes where they affect 
membrane fluidity and membrane permeability (36) and that measurement of erythrocyte 
DHA and EPA enrichment is considered a good proxy for omega-3 fatty acid enrichment and 
bioavailability in liver (37). However, based on our results, PNPLA3 I148M is involved in 
DHA/EPA mobilization in liver and subjects with PNPLA3 (I148M) GG genotype have lower 
levels of DHA (38). Additionally, omega-3 fatty acids decrease the expression of sterol 
response element binding protein 1c (SREBP1c), a key regulatory factor in hepatic 
lipogenesis (39), and recently it has been shown that carriers of the PNPLA3 148M allele 
have decreased de novo lipogenesis (22). Thus, it is possible that the lack of response to 
DHA+EPA treatment in decreasing liver fat % in subjects with PNPLA3 I148 MM could be due 
to the fact that these subjects already have low levels of de novo lipogenesis.  That said, it is 
not known whether PNPLA3 (I148M) GG genotype affects the incorporation of DHA (or EPA) 
into the liver lipid droplet, although recent evidence in a small study in children suggests 
that the PNPLA3 (I148M) GG genotype attenuates the benefit of DHA to decrease liver fat 
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(40). These data in children are in agreement with, and are extended by, our data, showing 
PNPLA3 (I148M) GG genotype is associated with lower levels of DHA enrichment. We show 
for the first time that the PNPLA3 (I148M) GG genotype is associated with a ~1 SD decrease 
(i.e. a 1.2% decrease) in erythrocyte DHA enrichment (unstandardized B coefficient -1.02 
(95%CI -1.97, -0.07), p=0.036). A 1 SD decrease in % DHA enrichment means that most 
individuals with the PNPLA3 GG genotype do not achieve the 2% DHA enrichment threshold 
that we have shown was necessary to achieve satisfactory reductions in liver fat in this 
cohort (5). Since our data show that higher levels of % DHA enrichment are associated with 
lower levels of liver fat (5), it is noteworthy that most patients with PNPLA3 (I148M) GG 
genotype do not achieve high levels of % DHA enrichment. Similarly, others have shown an 
effect of PNPLA3 genotype to modify treatment effect and a recent research study by 
Dongiovanni et al. (41) has shown that statin treatment was associated with a reduction in 
liver fat content and inflammation in individuals with NAFLD, carrying the PNPLA3 (I148I) CC 
genotype. The effect was absent in those with the PNPLA3 (I148I) GG genotype. 
The mechanism by which PNPLA3 (I148M) GG genotype affects fasting TG concentration is 
uncertain. Hyysalo et al. showed in non-obese people with NAFLD that the PNPLA3 (I148M) 
GG genotype is associated with hepatic hydrolysis of TG, reducing hepatic VLDL secretion 
(17) but it is uncertain whether PNPLA3 (I148M) GG genotype modifies any change in 
triglyceride concentrations induced by an intervention. 4 g of DHA+EPA (as Omacor or 
Lovaza) contains similar amounts of DHA (1520 mg) and EPA (1840 mg) as ethyl esters and 
our data suggest that a greater TG-lowering effect was associated with EPA enrichment 
rather than DHA enrichment. Our data (Table 4) show the factors that were associated with 
end of study fasting serum triglyceride concentrations (adjusting for baseline measurement 
and other confounders and covariates). These data show that many factors (but not PNPLA3 
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or TM6SF2 genotypes) were independently associated with triglyceride concentrations and, 
as expected, capsule count was independently associated with end of study triglyceride 
concentration. This finding is also consistent with licensing data for Omacor for the 
treatment for high serum triglyceride concentrations, where 4 g per day is the highest 
licenced dose, and 4 g is more effective in lowering serum triglyceride concentrations than 2 
to 3 g/day. It is possible that PNPLA3 (I148M) genotype only influences VLDL secretion (and 
thereby fasting triglyceride concentrations), when there are specific hepatic lipids available 
for incorporation into the secreted VLDL particle (42). Thus, it is plausible that PNPLA3 
(I148M) genotype may have little or no effect on VLDL levels when there is a modification in 
the quality of fatty acids and the type of hepatic lipid content (20) (e.g. as may occur after 
DHA treatment).  
Our study has strengths but also some limitations. The main limitation is the small sample 
size. However this study is the first study to test the effects of the PNPLA3 (I148M) and 
TM6SF2 (E167K) genotypes on relevant end points in NAFLD as part of an intervention trial 
testing the effects of high dose DHA+EPA treatment in adults. This study was a sub-study of 
the main trial whose primary end point was to test improvements in liver disease per se, 
rather than changes in fasting TG. We have presented data showing the effects of genotypes 
on change in % liver fat and change in serum triglyceride in NAFLD, rather than test the 
effect of genotypes on change in liver fibrosis biomarkers or other biomarkers of NAFLD 
severity that are known to be affected by PNPLA3 (I148M) and TM6SF2. The reason for this 
(as reported previously) was that these measures did not change between baseline and end 
of study during the trial (5). The sample size calculation for the trial has been reported 
previously (26) and was based on change in liver fat % and not changes in serum TG 
concentration. The strengths of our study are the randomised double blind placebo-
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controlled trial design that also included very detailed phenotyping of the patient cohort 
that enabled measurement of many potential confounders and a precise, quantitative 
measurement of % liver fat at baseline and at the end of study.   
In conclusion, DHA enrichment and loss of weight during the randomised double blind 
placebo controlled trial both independently decreased end of study % liver fat, adjusting for 
baseline % liver fat and all other measured covariates and confounders. PNPLA3 (I148M) 
GG, but not TM6SF2 genotypes, was strongly and negatively associated with DHA tissue 
enrichment and was associated with markedly higher (~10%) end of study liver fat levels. In 
contrast, end of study fasting triglyceride concentrations were strongly associated with % 
EPA enrichment but not PNPLA3 (I148M) or TM6SF2 (E167K) genotypes.  
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Table 1. Baseline and end of study biochemical and anthropometric characteristics 
 Placebo group DHA+EPA group 
Variables Baseline End of study p-value Baseline End of study p-value 
Age (y) 54.0 (9.6) 55.4 (9.6) n/a 48.6 (11.1) 50.1 (11.1) n/a 
Sex (M/F) 35/17 32/16 n/a 25/26 23/24 n/a 
Weight (kg) 94.5 (15.8) 90.4 (16.3) 0.76 96.5 (17) 94.1 (13) 0.38 
BMI (kg/m2) 32.4 (4.5) 30.8 (4.5) 0.74 34.0 (5.8) 33.4 (4.9) 0.30 
Prudent Diet Score*  0.09 (0.97) -0.07(0.9) 0.46 -0.1 (1.0) 0.03 (1.0) 0.55 
Alcohol intake (Units/week) 6.3 6.8 0.88 2.3 2.2 0.67 
Waist circumference (cm) 108.1 (11.5) 107.7 (10.3) 0.65 114.4 (13.4) 112.3 (10.4) 0.96 
Diastolic blood pressure 
(mmHg) 
86.3 (7.4) 82.9 (6.5) 0.75 85.4 (12.3) 81.7 (8.2) 0.006 
Systolic blood pressure 
(mmHg) 
137.7 (15.1) 133.9 (11.3) 0.13 138.2 (17.4) 133.3 (13.7) 0.004 
Fasting plasma glucose 
(mmol/L) 
6.2 (2.0) 6.7 (3.0) 0.07 6.2 (1.2) 6.1 (2.0) 0.77 
Fasting plasma insulin 
(μUnit/ml ) 
11.7 (11.2) 10.2 (9.3) 0.68 12.3 (7.1) 13.9 (6.4) 0.18 
HbA1c (%) 6.7 (1.2) 6.0 (2.0) 0.18 5.9 (0.9) 5.7 (2.0) 0.64 
Serum triglycerides (mmol/L) 1.5 (0.5) 1.8 (0.6) 0.05 1.8 (0.7) 1.5 (1.2) 0.018 
Serum cholesterol (mmol/L) 4.5 (0.8) 4.8 (1) 0.28 4.9 (1.1) 4.7 (1.1) 0.17 
LDL-cholesterol (mmol/L) 2.7 (0.7) 2.8 (0.8) 0.38 3.0 (0.9) 2.8 (0.9) 0.12 
HDL-cholesterol (mmol/L) 1.1 (0.3) 1.1 (0.2) 0.91 1.0 (0.2) 1.1 (0.3) < 0.0001 
ALT (IU/L) 59.5 (45) 48.5 (25) 0.03 55.0 (51) 44.0 (34) 0.89 
AST (IU/L) 50.0 (25) 35.0 (17) 0.02 39.0 (24) 30.0 (27) 0.97 
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Variables that are normally distributed are expressed as mean (standard deviation (SD)). Variables that are 
non-normally distributed are expressed as median (inter-quartile range (IQR)). 
*Prudent Diet Score (continuous variable derived from food frequency questionnaire, see (26) 
  
DEXA total fat mass (g) 
33252 
(8734) 
30822 (8136) 0.34 38128 (10565) 
35694 
(8061.6) 
0.09 
DEXA total lean mass (g) 
59017 
(11344) 
56396 
(11237) 
0.14 56353 (11564) 
56218 
(10799) 
0.61 
DEXA andro/gynoid (ratio) 1.2 (0.2) 1.2 (0.1) 0.13 1.2 (0.1) 1.1 (0.1) 0.72 
MRI subcutaneous fat (%) 30.4 (9.7) 28.8 (9) 0.43 35.4 (10.5) 32.0 (9.6) 0.47 
MRI visceral fat (%) 16.7 (4.7) 16.5 (5.4) 0.36 15.2 (5.1) 15.9 (4.7) 0.67 
MRS liver fat % 
21.7 
(13.7, 32.3) 
19.7 
(11.3, 28.0) 
0.006 
23.0 (12.0, 
47.5) 
16.3 (9.0, 
30.7) 
0.01 
Erythrocyte DHA (%) 
enrichment 
4.1 (1.6) 5.0 (1) 0.002 3.8 (1.2) 7.1 (1.3) < 0.0001 
Erythrocyte EPA (%) 
enrichment 
0.9 (0.4) 1.0 (0.2) 0.17 0.8 (0.3) 2.4 (1.8) < 0.0001 
Fibrates n  4 4 1.0 3 5 0.5 
Statins n  23 23 1.0 19 24 0.06 
Ezetimibe n 5 3 0.5 1 2 1.0 
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Table 2. Baseline characteristics according to PNPLA3 (I148M) genotype  
Phenotypes 
Genotypes  
CC 
N=42 
CG 
N=43 
GG 
N=13 
P value 
(difference 
between 
groups) 
Weight (kg) 96.8 (20.2) 97.9 (15.4) 89.3 (10.8) 0.5 
BMI (kg/m2) 34.6 (6.5) 33.2 (4.8) 31.7 (4.5) 0.2 
Fasting plasma glucose 
(mmol/L) 
5.3 (1.9) 5.5 (1.2) 5.4 (2.0) 0.3 
HOMA-IR 2.5 (2.4) 3.1 (4.6) 2.6 (1.1) 0.3 
Serum triglyceride 
(mmol/L) 
1.6 (1.2) 1.7 (0.9) 1.4 (0.3) 0.4 
Serum cholesterol 
(mmol/L) 
4.9 (0.9) 4.6 (1.1) 4.6 (0.7) 0.3 
HDL-cholesterol 
(mmol/L) 
1.1 (0.4) 1.1 (0.3) 1.1 (0.3) 0.9 
LDL-cholesterol 
(mmol/L) 
3.0 (0.9) 2.7 (0.9) 2.9 (0.7) 0.5 
ALT (IU/L) 53 (44) 55 (33) 70 (65) 0.4 
AST (IU/L) 38 (21) 39 (26) 45 (54) 0.5 
MRS liver fat % 26.7 (20.9) 28.8 (19.9) 33.5 (17.5) 0.5 
Erythrocyte EPA (%) 
baseline 
0.8 (0.3) 0.9 (0.4) 0.7 (0.3) 0.1 
Erythrocyte DHA (%) 
baseline 
3.7 (1.2) 4.3 (1.4) 3.6 (1.4) 0.03 
Variables that are normally distributed are expressed as mean (standard deviation (SD)). Variables that are 
non-normally distributed are expressed as median (inter-quartile range (IQR)). (CC = 148II, C/G=148 IM, GG= 
148MM). 
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Table 3. Baseline characteristics according to TM6SF2 genotype  
Phenotypes 
Genotypes  
CC CT+TT 
P value 
(difference 
between 
groups) 
Weight (kg) 94.9 (15.1) 98.5 (20.9) 0.5 
BMI (kg/m2) 32.6 (4.5) 35.4 (8.1) 0.05 
Fasting plasma glucose 
(mmol/L) 
6.3 (2.7) 6.1 (1.3) 0.6 
HOMA-IR 2.7 (2.9) 4.0 (5.8) 0.7 
Serum triglyceride 
(mmol/L) 
1.6 (1.1) 1.5 (0.7) 0.02 
Serum cholesterol 
(mmol/L) 
4.7 (1.0) 4.5 (0.9) 0.1 
HDL-cholesterol 
(mmol/L) 
1.0 (0.4) 1.0 (0.3) 0.6 
LDL-cholesterol 
(mmol/L) 
2.8 (1.0) 2.8 (0.6) 0.3 
ALT (IU/L) 55.0 (51) 55.0 (58) 0.8 
AST (IU/L) 42.0 (24) 39.0 (40) 0.8 
MRS liver fat % 28.5 (20.3) 29.0 (19.1) 0.9 
Erythrocyte EPA (%) 
baseline 
1.1 (1.4) 0.5 (0.7) 0.1 
Erythrocyte DHA (%) 
baseline 
4.0 (1.4) 4.1 (0.8) 0.6 
Variables that are normally distributed are expressed as mean (standard deviation (SD)). Variables that are 
non-normally distributed are expressed as median (inter-quartile range (IQR)). (CC = 148II, C/G=148 IM, GG= 
148MM). 
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Table 4. Factors independently associated with end of study liver fat percentage with 
DHA+EPA treatment 
 
 
 
 
 
 
 
 
 
Factors included in the model, age, sex, baseline liver fat %, PNPLA3 genotype, TMS6SF2 
genotype, % DHA enrichment (end of study – baseline % enrichment), baseline serum 
triglyceride, total fat mass, change in M65 (between end of study and baseline), BMI, 
diabetes, change in weight, use of orlistat at baseline, use of L thyroxine at baseline and 
capsule count. R2=0.54, p<0.0001.  
  
Variables 
Unstandardised 
B coefficient  
95%CI p-value 
Baseline liver fat (%) -0.39 -0.60, -0.28 <0.0001 
Total body fat mass (kgs) 0.58 0.09, 1.07 0.021 
Change in body weight (kg) 0.79 0.25, 1.32 0.004 
PNPLA3 (I148M) genotype GG 9.5 2.53, 16.39 0.008 
% DHA enrichment -1.50 -2.82, -0.19 0.025 
27 
 
 
Table 5. Factors independently associated with end of study fasting triglyceride 
concentration with DHA+EPA treatment 
 
 
 
 
 
 
 
 
 
 
 
Fact
ors included in the model, age, sex, baseline liver fat %, PNPLA3 genotype, TMS6SF2 
genotype, % EPA enrichment (end of study – baseline % enrichment), BMI, total fat mass, 
diabetes, change in M65 (between end of study and baseline), change in weight, triglyceride 
concentration at baseline, and use of orlistat, L thyroxine, fibrates, beta blockers, and 
thiazide diuretics at baseline and capsule count. (N.B. PNPLA3 genotype GG (I148M) (B 
coefficient -0.02 (95%CI -0.52, 0.49, p=0.95). Final model R2=0.56, p<0.0001).  
  
Variables 
Unstandardised B 
coefficient  
95%CI p-value 
Age (y) -0.03 -0.05, -0.02 <0.0001 
Being male 0.54 0.13, 0.97 0.011 
Baseline triglycerides (mmol/L)  -0.47 -0.60, -0.34 <0.0001 
Total body fat mass (kg) -0.03 -0.05, -0.01 0.003 
Capsule count -0.24 -0.45, -0.03 0.025 
Use of beta blockers 0.85 0.07, 1.63 0.034 
% EPA enrichment -0.19 -0.31, -0.07 0.002 
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Table 6. Adjusted mean differences for change in liver fat percentage, change in serum 
fasting triglyceride concentration and change in DHA percentage enrichment with 
DHA+EPA treatment, according to PNPLA3 genotype 
Phenotypes 
Genotypes 
CC 
N=42 
CG 
N=43 
GG 
N=13 
Adjusted mean change in 
liver fat % (95%CI) 
-7.05 (-10.77, -3.33)  -7.30 (-10.75, -3.85)  2.75 (-4.22, 9.73)  
*Adjusted mean change 
in triglyceride (mmol/L) 
(95%CI)  
-0.12 (-0.41, 1.62)  -0.09 (-0.36, 0.17) -0.20 (-0.71, 0.31) 
§Adjusted mean change 
in DHA (%) (95%CI) 
1.84 (1.27, 2.41) 
 
2.06 (1.52, 2.60) 
 
0.75 (-0.23, 1.72)  
 
 
Change in liver fat %: ANCOVA model adjustments: age, sex, baseline liver fat %, PNPLA3 
genotype, TM6SF2, BMI, diabetes, % DHA enrichment (end of study – baseline % 
enrichment), baseline serum triglyceride, total fat mass, change in M65 (between end of 
study and baseline), change in weight, use of orlistat at baseline, use of L thyroxine at 
baseline and capsule count. 
Pairwise comparisons C/C v GG, p=0.02 and C/G v GG p=0.012. 
 
*Change in triglycerides: ANCOVA model adjustments: age, sex, baseline liver fat %, PNPLA3 
genotype, TM6SF2, BMI, diabetes, % EPA enrichment (end of study – baseline % 
enrichment), total fat mass, change in M65 (between end of study and baseline), change in 
weight, triglyceride concentration at baseline, and use of orlistat, L thyroxine, fibrates, beta 
blockers, and thiazide diuretics at baseline and capsule count. Pairwise comparisons C/C v 
GG, p=0.8 and C/G v GG p=0.71 
 
§Change in DHA % enrichment: ANCOVA model adjustments: , age, sex, baseline liver fat %, 
PNPLA3 genotype, TM6SF2, BMI, diabetes, % DHA baseline, baseline serum triglyceride, 
total fat mass, change in M65 (between end of study and baseline), change in weight, use of 
orlistat at baseline, use of L thyroxine at baseline and capsule count. Pairwise comparisons 
C/C v GG, p=0.06 and C/G v GG p=0.023 
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Supplementary Table: Differences between baseline and end of study of participant characteristics 
according to PNPLA3 genotype 
Phenotypes 
Genotypes Placebo  Genotypes Active  
CC CG GG 
P 
value 
CC CG GG 
P 
value 
Age 54 55 54 0.9 52 45 49 0.1 
Sex 
(Male/Female) 
12/7 14/6 7/3 n/a 9/14 13/10 1/2 n/a 
Diabetes (y/n) 12/7 15/5 5/5 n/a 15/8 15/8 3/0 n/a 
Waist 
circumference 
(cm) 
2.8 
(8.3) 
-1.8 
(4.4) 
0.4 
(4.0) 
0.07 
-0.4 
(3.4) 
0.8 
(5.3) 
-5 
(2.1) 
0.2 
Weight (kg) 
-2.0 
(4.0) 
1.6 
(4.6) 
-0.65 
(3.7) 
0.03 
0.7 
(3.6) 
0.2 
(5.6) 
2.8 
(1.6) 
0.7 
BMI (kg/m2) 
-0.6 
(1.4) 
0.5 
(1.6) 
-0.3 
(1.4) 
0.04 
0.3 
(1.3) 
0.1 
(1.8) 
0.8 
(0.6) 
0.8 
Serum 
triglyceride 
(mmol/L) 
0.0 
(0.6) 
0.2 
(1.2) 
0.3 
(0.8) 
0.5 
-0.1 
(1.2) 
-0.3 
(1.0) 
0.0  
(n/a) 
0.6 
ALT (IU/L) 
-1.0 
(23) 
-3 
(21.7) 
-14 
(34.0) 
0.4 
3.0 
(37.2
) 
-3.0 
(20.0) 
3.0  
(n/a) 
0.4 
AST (IU/L) 
-3.0 
(17) 
-1.0 
(10.7) 
-9.0 
(31.5) 
0.3 
-0.5 
(20.7
) 
1.0 
(14.0) 
-1.5 
(n/a) 
0.8 
MRS liver fat 
% 
-7.6 
(10) 
-3.7 
(7.6) 
-0.4 
(9.3) 
0.1 
-6.3 
(15.2
) 
-10.2 
(18.8) 
8.1 
(4.0) 
0.3 
Erythrocyte 
EPA (%)  
0.1 
(0.3) 
-0.04 
(0.3) 
0.1 
(0.3) 
0.1 
1.9 
(1.4) 
2.1 
(1.3) 
1.0 
(0.3) 
0.5 
Erythrocyte 
DHA (%) 
3.6 
(1.4) 
4.7 
(1.4) 
3.8 
(1.4) 
0.05 
3.8 
(0.9) 
4.1 
(1.5) 
3.1 
(1.0) 
0.3 
 
Variables that are normally distributed are expressed as mean (standard deviation (SD)). Variables that are 
non-normally distributed are expressed as median (inter-quartile range (IQR)). (CC = 148II, C/G=148 IM, GG= 
148MM). P value (difference between groups) 
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